Entera Bio Ltd. has established a U.S. Headquarters in the Boston area and has appointed Jonathan Lieber as its U.S.-based chief financial officer. Mr. Lieber will be responsible for all investor relations, finance and administrative functions, and will lead the company’s future financing efforts to support growth initiatives.

Entera Bio Inc., the company’s wholly owned Delaware subsidiary, established its U.S. Headquarters in Wellesley, MA to support future growth in financial, business development and clinical / regulatory staff. The Company’s R&D operations will continue to be located in Jerusalem, Israel, where much of the Company’s collaboration, clinical and CMC efforts will expand to support our anticipated growth.

“We are pleased to have an accomplished executive of Jon’s caliber join Entera Bio.  We welcome his long experience at emerging life science companies and his strong investor and banking relationships,” said Adam Gridley, chief executive officer of Entera.  “As the company builds its presence with its stakeholders, the addition of Jon as our U.S.-based CFO will be critical to support our future growth, and our lead clinical programs and in our business development efforts.”

Mr. Lieber’s background includes financial and executive management roles at emerging and growth-stage life science companies. As a CFO, he has raised more than $300 million of equity and debt in public and private securities offerings, including a $110 million IPO at Altus Pharmaceuticals, and led strategic and business development transactions including the successful sale of Xcellerex to GE Healthcare. He currently serves as a managing director of Danforth Advisors, and most recently served as CFO of Histogenics, a cell therapy company developing products for the orthopedics market.